Megan Tooley, Cardiovascular Roundtable
There is no question the emergence of transcatheter valve technologies—specifically transcatheter aortic valve replacement (TAVR)—has elicited unprecedented excitement from the cardiovascular community in recent years. However, despite this enthusiasm, the reality is only a portion of hospitals will meet the strict resource and volume requirements necessary to become TAVR sites in the near future.
This may leave many of you wondering, “So what if we’re not a TAVR program? Is there still a place for us in the valve market?” You’re not alone, and as we explore in our national meeting series, your options for treating valve disease and disorders do not end at TAVR.
Learn how one Roundtable member is ensuring their patients have access to a full range of valve services—even if they’re not the TAVR program.
So you're not a TAVR program—Now what?
This past week the Centers for Medicare and Medicaid Services (CMS) initiated a national coverage analysis (NCA) for transcatheter aortic-valve implantation (TAVI), effectively beginning the process to determine Medicare beneficiary coverage eligibility for the device. The announcement of the initiated NCA comes ahead of the Food and Drug Administration’s (FDA) expected approval of the first TAVI device for commercial sale, likely in November 2011, if not sooner.
CMS Initiates Coverage Analysis for TAVI